Heartflow to Present AI Technology at 44th J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Globenewswire
- Technology Showcase: Heartflow will present its AI technology for coronary artery disease at the 44th J.P. Morgan Healthcare Conference on January 13, 2026, which is expected to attract attention from over 1,400 global institutions, thereby enhancing its market influence.
- Clinical Validation: Heartflow's AI-driven solutions have been validated through over 100 studies involving more than 365,000 patients, demonstrating high accuracy and reproducibility in clinical practice, further solidifying its leadership in cardiovascular care.
- Data Foundation: The proprietary data pipeline built from over 160 million annotated CTA images powers advanced AI models that deliver highly accurate clinical insights, aiding in the management of care for over 500,000 patients worldwide.
- Seamless Integration: With upgraded workflows, Heartflow provides instant final quality-reviewed analyses, enabling clinicians to swiftly transition from diagnosis to decision-making, significantly improving medical efficiency.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HTFL is 38.60 USD with a low forecast of 35.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.




